arrow
G

Gaia Moretta

dermatology
H指数:14
被引数:734

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CXCL13 as a simple and promising blood biomarker for differentiating Sézary syndrome from mycosis fungoides and other confounding chronic inflammatory skin diseases

CXCL13作为区分Sézary综合征与真菌状肉芽肿及其他混淆性慢性炎症性皮肤病的简单且具有前景的血液生物标志物

2026-04-100
OA
Genetic profiling of patients with atopic dermatitis reveals immune and skin barrier variants associated with generalized eczema and optimal response to Dupilumab therapy

特应性皮炎患者的基因谱分析揭示了与泛发性湿疹和Dupilumab治疗最佳反应相关的免疫和皮肤屏障变异

2026-04-100
OAAI
Anti-IL-17 and Anti-IL-23 Therapies Modulate Serum Biomarkers of Intestinal Dysbiosis and Oxidative Stress Linked to Cardiovascular Risk in Patients with Psoriasis

抗IL-17和抗IL-23疗法可调节与心血管风险相关的银屑病患者血清肠道菌群失调和氧化应激生物标志物。

2025-11-030
OAAI
Long-Term Persistence with Guselkumab: A 5-Year Multicenter Retrospective Study across 14 Dermatology Centers in Italy

guselkumab的长期持续性:一项在意大利14个皮肤病学中心进行的为期5年的多中心回顾性研究

2025-10-010
OAAI
Real-world analysis of IL-23 inhibitors in patients with moderate-to-severe psoriasis and early musculoskeletal symptoms

中重度银屑病患者早期肌肉骨骼症状中IL-23抑制剂的真实世界分析

2025-09-080
OA
Use of upadacitinib in the treatment of moderate to severe atopic dermatitis: patient profiling, dose selection, and therapy modulation, what does real-life teach us?

乌帕替尼在治疗中重度特应性皮炎中的应用:患者特征分析、剂量选择和治疗调整,现实世界能告诉我们什么?

2025-06-090
OA
Evaluating the Efficacy of Bimekizumab across the Different Sensitive Areas in Moderate-to-Severe Psoriasis: A 52-week Italian Multicenter Real-Life Lazio Experience

评估Bimekizumab在不同敏感区域治疗中重度银屑病的疗效:一项为期52周的意大利多中心真实世界拉齐奥经验

2025-04-110
OA
Effectiveness of Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: A Retrospective, Real-World Multicenter Study with a Focus on Obese and Multi-Failure Patients-IL PSO (Italian Landscape Psoriasis)
2025-02-080
OAAI
Effectiveness, speed of action and safety of brodalumab in elderly psoriasis patients: a multicenter real-world study - IL PSO (Italian Landscape Psoriasis)

布罗达鲁单抗在老年银屑病患者中的有效性、作用速度及安全性:一项多中心真实世界研究 - IL PSO(意大利银屑病全景)

2025-02-060
OA
A microarray-based IgE-molecular mimicry index (IgE-MMI): A biomarker for disease severity, clinical phenotypes, and therapeutic response in atopic dermatitis?
2024-11-040
PRE
2-Year Experience with Risankizumab in the Treatment of Plaque Psoriasis in Lazio Region, Italy
2023-09-191
OA
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year

接受guselkumab治疗长达1年的中至重度斑块状银屑病患者的真实结果

2022-06-226
OA
Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life study

Risankizumab治疗中重度银屑病: 一项多中心、回顾性、1年真实生活研究

2022-04-1319
OAAI
Predictive factors of lack of response to adalimumab among bio-naive patients suffering from moderate-to severe psoriasis: analysis of a multicenter data collection in Italy
2021-07-186
PREAI
Merkel Cell Carcinoma

默克尔细胞癌

2021-06-2314
OAAI